Table 11: Patient Characteristics, Visual Laser Ablation Versus TURP.
| Study, Year | Patients, No. (Treatment, control) | Inclusion criteria | Prostate size Mean (SD), mL | Mean follow-up (Months) | No. available for follow-up |
|---|---|---|---|---|---|
| Chacko et al. 2001(67) Multicentre trial (CLasP study) 3- arm |
148 (74, 74) |
ClasP trial acute patients: Acute painful urinary retention: Patients with BPH | NR | VLAP: 7.3 months TURP: 7.5 months |
VLAP: 70 TURP: 73 |
| Gujral et al. 2000 (68) Multicentre trial (CLasP study) 3-arm |
82 (38, 44) |
ClasP trial chronic patients: Chronic retention: Patients with BPH with prostate size ≤120 cc; IPSS ≥8 with patient and physician agreement that symptoms justified intervention; low urinary flow rate <15, <13, or <10 mL/s when voided volume was >200, 150–200, and 100–149 mL respectively | 40.7 (19.9) 49.7 (21.8) |
7.5 months | VLAP: 38 TURP: 44 |
| Donovan et al. 2000 (69) Multicentre trial (ClasP trial) 3-arm |
234 (117, 117) Plus conservative management arm = 106 |
ClasP trial symptomatic patients: No acute or chronic urinary retention: Patients with BPH with prostate size ≤120 cc; IPSS ≥8 with patient and physician agreement that symptoms justified intervention; low urinary flow rate <15, <13, or <10 mL/s when voided volume was >200, 150–200, and 100–149 mL respectively | VLAP: 38.1 (19.1) TURP: 40.7 (21.4) |
7.5 months | VLAP: 116 TURP: 115 |
BPH refers to benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; NR, not reported; SD, standard deviation; TURP, transurethral resection of the prostate; VLAP, visual laser ablation of the prostate